305335-31-3
305335-31-3 結構式
基本信息
((S)-1-carboxy-2-(1-(3,5-dichlorobenzyl)-1H-imidazol-5-yl)ethyl)-L-leucine
L-Histidine, N-[(1S)-1-carboxy-3-methylbutyl]-3-[(3,5-dichlorophenyl)methyl]-
物理化學性質
| 報價日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
| 2026/07/06 | S8940 | MLN-4760 MLN-4760 | 305335-31-3 | 5mg | 5172.32元 |
| 2026/07/06 | S8940 | MLN-4760 MLN-4760 | 305335-31-3 | 25mg | 12768.5元 |
| 2026/06/05 | HY-19414 | MLN-4760 MLN-4760 | 305335-31-3 | 1mg | 1550元 |
常見問題列表
| Target | Value |
|
ACE2
(Cell-free assay) | 0.44 nM |
|
CPDA
(Cell-free assay) | 27 μM |
MLN-4760 is a potent and selective human ACE2 inhibitor (IC 50 , 0.44 nM), with excellent selectivity (>5000-fold) versus related enzymes human testicular ACE (IC 50 , >100 μM) and bovine carboxypeptidase A (CPDA; IC 50 , 27 μM). MLN-4760 effectively quenches cleavage of the 7-Mca-YVADAPK(Dnp) in rhACE2. MLN-4760 shows pIC 50 at rhACE2 of 8.5±0.1 and at rhACE of 4.4±0.2. MLN-4760 also shows pIC 50 at rhACE2 of 4.7±0.1, 6.9±0.1 and at ACE of 4.4±0.1, 6.2±0.1 in murine heart and mononuclear cells (MNCs), resepctively.
MLN-4760 (100 μM, intracerebroventricular infusion for five days) significantly worsens neurological function at 4 h and 3 d post-stroke without significantly increasing infarct volume.